Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax
MOSCOW, Jan 14 (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.
Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit. (Reporting by Alexander Marrow; editing by John Stonestreet)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.